
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Launching and commercializing complex therapies requires agility, specialized expertise and the ability to adapt as market conditions evolve. This POV explores how an integrated commercialization model can give biopharma teams flexible access to end-to-end or select capabilities while helping reduce cost, complexity and overall risk. Through real-world case studies, readers will learn how scalable infrastructure, experienced commercial leadership and data-driven execution can support successful launches, global expansion and continued value creation across the product life cycle.





